Breaking Finance News

A statement released earlier today by JPMorgan Chase & Co. about Luminex Corporation (NASDAQ:LMNX) bumps the target price to $22.00

Luminex Corporation (NASDAQ:LMNX) had its estimated target price upped to $22 by JPMorgan Chase & Co. in an issued report released 8/18/2016. The increased target price suggests a possible upside of 0.01% based on the company’s previous stock close price.

Showing a price of $21.84, Luminex Corporation (NASDAQ:LMNX) traded 0.46% lower on the day. The last stock price close is up 6.63% from the two hundred day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. Luminex Corporation has logged a 50-day moving average of $21.54 and 200-day moving average of $20.50. Volume of trade was was up over the average, with 282,132 shares of LMNX changing hands over the typical 223,564 shares.

Recent Performance Chart:

Luminex Corporation (NASDAQ:LMNX)

Luminex Corporation has a price-earnings of 23 with a one-year low of $16.16 and a one-year high of $23.75 and has a total market value of $0.0.

General Company Details For Luminex Corporation (NASDAQ:LMNX)

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to various types of testing laboratories. The Company’s assay products are focused on three segments of the molecular diagnostic testing market: human genetics, and personalized medicine and infectious disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.